These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Ritt MJ; Hillebrand-Haverkort ME; ten Veen JH Acta Chir Plast; 2001; 43(2):54-6. PubMed ID: 11505710 [TBL] [Abstract][Full Text] [Related]
3. HIV-associated facial lipoatrophy--review of current therapy options. Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH; Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554 [TBL] [Abstract][Full Text] [Related]
4. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Terry L; Sprinz E; Stein R; Medeiros NB; Oliveira J; Ribeiro JP Med Sci Sports Exerc; 2006 Mar; 38(3):411-7. PubMed ID: 16540826 [TBL] [Abstract][Full Text] [Related]
5. [Therapy of lipodystrophy: no clear answers to clinical questions]. Volkert R Dtsch Med Wochenschr; 2001 Dec; 126(49):A1118. PubMed ID: 11791516 [No Abstract] [Full Text] [Related]
6. HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution. Balasubramanyam A; Sekhar RV Res Initiat Treat Action; 2006; 12(1):5-11. PubMed ID: 17153230 [No Abstract] [Full Text] [Related]
8. Body shape changes: where are we? Munk Robert Res Initiat Treat Action; 2006; 12(1):13-6. PubMed ID: 17153231 [No Abstract] [Full Text] [Related]
9. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy. Phillips DR; Hay P J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527 [TBL] [Abstract][Full Text] [Related]
10. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment. Crook M Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292 [TBL] [Abstract][Full Text] [Related]
12. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F; Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053 [TBL] [Abstract][Full Text] [Related]
13. Lipodystrophy: a new phenomenon? Boyle BA AIDS Read; 1999; 9(1):15-7. PubMed ID: 12728877 [No Abstract] [Full Text] [Related]
14. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343 [TBL] [Abstract][Full Text] [Related]
15. Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy. Deonarain J; Ramdial PK; Singh B Int J Surg Pathol; 2008 Apr; 16(2):171-5. PubMed ID: 18417674 [TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy-induced lipodystrophy. Behera V; Randive M; Sundaray S; Murty MS BMJ Case Rep; 2015 Feb; 2015():. PubMed ID: 25678613 [No Abstract] [Full Text] [Related]
17. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review. Aberg JA Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827 [TBL] [Abstract][Full Text] [Related]